166 related articles for article (PubMed ID: 35324454)
21. Genetic and epigenetic differences of benign and malignant pheochromocytomas and paragangliomas (PPGLs).
Khatami F; Mohammadamoli M; Tavangar SM
Endocr Regul; 2018 Jan; 52(1):41-54. PubMed ID: 29453919
[TBL] [Abstract][Full Text] [Related]
22. Pseudohypoxic pheochromocytomas and paragangliomas dominate in children.
Redlich A; Pamporaki C; Lessel L; Frühwald MC; Vorwerk P; Kuhlen M
Pediatr Blood Cancer; 2021 Jul; 68(7):e28981. PubMed ID: 33682326
[TBL] [Abstract][Full Text] [Related]
23. Semiquantitative 123I-Metaiodobenzylguanidine Scintigraphy to Distinguish Pheochromocytoma and Paraganglioma from Physiologic Adrenal Uptake and Its Correlation with Genotype-Dependent Expression of Catecholamine Transporters.
van Berkel A; Rao JU; Lenders JW; Pellegata NS; Kusters B; Piscaer I; Hermus AR; Plantinga TS; Langenhuijsen JF; Vriens D; Janssen MJ; Gotthardt M; Timmers HJ
J Nucl Med; 2015 Jun; 56(6):839-46. PubMed ID: 25883126
[TBL] [Abstract][Full Text] [Related]
24. Germline mutations and genotype-phenotype correlations in patients with apparently sporadic pheochromocytoma/paraganglioma in Korea.
Kim JH; Seong MW; Lee KE; Choi HJ; Ku EJ; Bae JH; Park SS; Choi SH; Kim SW; Shin C; Kim SY
Clin Genet; 2014 Nov; 86(5):482-6. PubMed ID: 24134185
[TBL] [Abstract][Full Text] [Related]
25. Metastatic Pheochromocytomas and Abdominal Paragangliomas.
Granberg D; Juhlin CC; Falhammar H
J Clin Endocrinol Metab; 2021 Apr; 106(5):e1937-e1952. PubMed ID: 33462603
[TBL] [Abstract][Full Text] [Related]
26. Preclinical evaluation of targeted therapies in Sdhb-mutated tumors.
Moog S; Salgues B; Braik-Djellas Y; Viel T; Balvay D; Autret G; Robidel E; Gimenez-Roqueplo AP; Tavitian B; Lussey-Lepoutre C; Favier J
Endocr Relat Cancer; 2022 May; 29(6):375-388. PubMed ID: 35348472
[TBL] [Abstract][Full Text] [Related]
27. Rationale and evidence for sunitinib in the treatment of malignant paraganglioma/pheochromocytoma.
Joshua AM; Ezzat S; Asa SL; Evans A; Broom R; Freeman M; Knox JJ
J Clin Endocrinol Metab; 2009 Jan; 94(1):5-9. PubMed ID: 19001511
[TBL] [Abstract][Full Text] [Related]
28. Deep Membrane Proteome Profiling Reveals Overexpression of Prostate-Specific Membrane Antigen (PSMA) in High-Risk Human Paraganglioma and Pheochromocytoma, Suggesting New Theranostic Opportunity.
Vit O; Patel M; Musil Z; Hartmann I; Frysak Z; Miettinen M; Pacak K; Petrak J
Molecules; 2021 Oct; 26(21):. PubMed ID: 34770976
[TBL] [Abstract][Full Text] [Related]
29. Cytocidal activities of topoisomerase 1 inhibitors and 5-azacytidine against pheochromocytoma/paraganglioma cells in primary human tumor cultures and mouse cell lines.
Powers JF; Korgaonkar PG; Fliedner S; Giubellino A; Pacak K; Sahagian GG; Tischler AS
PLoS One; 2014; 9(2):e87807. PubMed ID: 24516563
[TBL] [Abstract][Full Text] [Related]
30. HIF2α supports pro-metastatic behavior in pheochromocytomas/paragangliomas.
Bechmann N; Moskopp ML; Ullrich M; Calsina B; Wallace PW; Richter S; Friedemann M; Langton K; Fliedner SMJ; Timmers HJLM; Nölting S; Beuschlein F; Fassnacht M; Prejbisz A; Pacak K; Ghayee HK; Bornstein SR; Dieterich P; Pietzsch J; Wielockx B; Robledo M; Qin N; Eisenhofer G
Endocr Relat Cancer; 2020 Nov; 27(11):625-640. PubMed ID: 33112842
[TBL] [Abstract][Full Text] [Related]
31. Opposing effects of HIF1α and HIF2α on chromaffin cell phenotypic features and tumor cell proliferation: Insights from MYC-associated factor X.
Qin N; de Cubas AA; Garcia-Martin R; Richter S; Peitzsch M; Menschikowski M; Lenders JW; Timmers HJ; Mannelli M; Opocher G; Economopoulou M; Siegert G; Chavakis T; Pacak K; Robledo M; Eisenhofer G
Int J Cancer; 2014 Nov; 135(9):2054-64. PubMed ID: 24676840
[TBL] [Abstract][Full Text] [Related]
32. 15 YEARS OF PARAGANGLIOMA: Genetics and mechanism of pheochromocytoma-paraganglioma syndromes characterized by germline SDHB and SDHD mutations.
Baysal BE; Maher ER
Endocr Relat Cancer; 2015 Aug; 22(4):T71-82. PubMed ID: 26113606
[TBL] [Abstract][Full Text] [Related]
33. Management and outcome of metastatic pheochromocytomas/paragangliomas: an overview.
De Filpo G; Maggi M; Mannelli M; Canu L
J Endocrinol Invest; 2021 Jan; 44(1):15-25. PubMed ID: 32602077
[TBL] [Abstract][Full Text] [Related]
34. Personalized Management of Pheochromocytoma and Paraganglioma.
Nölting S; Bechmann N; Taieb D; Beuschlein F; Fassnacht M; Kroiss M; Eisenhofer G; Grossman A; Pacak K
Endocr Rev; 2022 Mar; 43(2):199-239. PubMed ID: 34147030
[TBL] [Abstract][Full Text] [Related]
35. New Insights into the Nuclear Imaging Phenotypes of Cluster 1 Pheochromocytoma and Paraganglioma.
Taïeb D; Pacak K
Trends Endocrinol Metab; 2017 Nov; 28(11):807-817. PubMed ID: 28867159
[TBL] [Abstract][Full Text] [Related]
36. Genotype-phenotype correlations in pheochromocytoma and paraganglioma: a systematic review and individual patient meta-analysis.
Crona J; Lamarca A; Ghosal S; Welin S; Skogseid B; Pacak K
Endocr Relat Cancer; 2019 May; 26(5):539-550. PubMed ID: 30893643
[TBL] [Abstract][Full Text] [Related]
37. Pheochromocytoma and paraganglioma: molecular testing and personalized medicine.
Burnichon N; Buffet A; Gimenez-Roqueplo AP
Curr Opin Oncol; 2016 Jan; 28(1):5-10. PubMed ID: 26599293
[TBL] [Abstract][Full Text] [Related]
38. PD-L1 expression and association with genetic background in pheochromocytoma and paraganglioma.
Hadrava Vanova K; Uher O; Meuter L; Ghosal S; Talvacchio S; Patel M; Neuzil J; Pacak K
Front Oncol; 2022; 12():1045517. PubMed ID: 36439433
[TBL] [Abstract][Full Text] [Related]
39. Succinate Mediates Tumorigenic Effects
Matlac DM; Hadrava Vanova K; Bechmann N; Richter S; Folberth J; Ghayee HK; Ge GB; Abunimer L; Wesley R; Aherrahrou R; Dona M; Martínez-Montes ÁM; Calsina B; Merino MJ; Schwaninger M; Deen PMT; Zhuang Z; Neuzil J; Pacak K; Lehnert H; Fliedner SMJ
Front Endocrinol (Lausanne); 2021; 12():589451. PubMed ID: 33776908
[TBL] [Abstract][Full Text] [Related]
40. Rationale for anti-angiogenic therapy in pheochromocytoma and paraganglioma.
Favier J; Igaz P; Burnichon N; Amar L; Libé R; Badoual C; Tissier F; Bertherat J; Plouin PF; Jeunemaitre X; Gimenez-Roqueplo AP
Endocr Pathol; 2012 Mar; 23(1):34-42. PubMed ID: 22183643
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
